about
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative diseaseMechanism of action of lenalidomide in hematological malignanciesWhat is the functional role of the thalidomide binding protein cereblon?Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemiaStructure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomideTumor necrosis factor-α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in miceTreatment of multiple myeloma bone disease: experimental and clinical data.Anti-inflammatory thalidomide improves islet grafts survival and functions in a xenogenic environmentThalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase.Inhibitory effects of phthalimide derivatives on the activity of the hepatic cytochrome P450 monooxygenases CYP2C9 and CYP2C19.Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease.Caprine pancreatic islet xenotransplantation into diabetic immunosuppressed BALB/c miceTeratogenic effects of thalidomide: molecular mechanisms.Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogsSafety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumabThalidomide Analogues Suppress Lipopolysaccharide-Induced Synthesis of TNF-α and Nitrite, an Intermediate of Nitric Oxide, in a Cellular Model of InflammationMechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.Protective effects of thalidomide on pulmonary injuries in a rat model of paraquat intoxication.Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.Determination of (4-(1,3-dioxo-1,3-dihydro-2H-isoindol- 2-yl)-N'-[(4-ethoxyphenyl) methylidene] benzohydrazide, a novel anti-inflammatory agent, in biological fluids by UPLC-MS/MS: Assay development, validation and in vitro metabolic stability studyThalidomide-induced limb abnormalities in a humanized CYP3A mouse modelPlasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.Emerging therapies for malignant glioma.Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors.Indeterminate cell histiocytosis in association with acute myeloid leukemia.The potential of immunomodulatory drugs in the treatment of solid tumors.Drug repositioning for orphan diseases.Deciphering the mystery of thalidomide teratogenicity.Lenalidomide in solid tumors.Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.Pericytes as targets in hereditary hemorrhagic telangiectasia.Angiogenesis in cancer: Anti-VEGF escape mechanismsThalidomide induces apoptosis in undifferentiated human induced pluripotent stem cells.Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.Glutamic acid and its derivatives: candidates for rational design of anticancer drugs.Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos.
P2860
Q21093232-F2B2D89C-3166-4D23-A01E-AA29BECB3114Q21198872-1279F60A-2E15-4450-8122-1D1BC2CA006BQ24635072-46A9AF47-A4AF-44F6-AD66-78D32C4E27E5Q27001318-9B8C86C1-D161-4D5F-9E8B-AADEFA0D1909Q27684738-E2B85FE2-F622-41BA-AACF-44FC714A0D4CQ30520539-0A097B0D-4313-4AFD-A1A9-AFD1BFDAD40DQ30868833-13A877B2-9086-4414-8DA5-973A1B517275Q33484188-7A91D9AE-CA8B-4113-AAE4-153DC53DBF81Q33569519-F03D3ED3-1516-4C38-95A9-F4FCEF2D6C76Q33616683-E7BFA800-3905-4955-9CA5-4CAE6455C225Q34584102-2A3FCC9F-A4EA-4F51-B6B1-893439A6FE72Q34637675-7A5CEDE7-4A1D-4899-8345-8C1443DB00FBQ34660391-6D698473-2706-4F61-8EBF-687DC2029897Q34661167-CEAC1B31-088A-4839-B1BB-D0D522E59EAFQ34666858-0F098740-73C6-4CBB-B785-B4428E75204EQ34999903-78564284-BF8B-4152-B1EF-501F5B59958BQ35121026-FF0F80EA-CCCA-423E-8F88-BBDF2C921D5CQ35171777-991BC181-1BAC-4FA4-8EC7-16B06B2DDD1FQ35832330-48A5580D-184E-4A15-A986-021991071307Q35895977-9C028B62-ED5E-4071-AECF-2F08B70D2575Q36330960-2687726D-3579-4C36-A57B-81E5F16285D2Q36332418-1546C00D-CFF0-458A-BDBA-B2F009A8C5AFQ36606177-D73A1D4B-BB39-4E80-ADCB-976FC0EB8CBCQ36936541-F4CB1D1C-8C14-45C4-8164-892A0436E095Q37014078-48D97309-4509-4A6C-AD24-B57D83944A5DQ37030800-E5512D01-25B0-4CD5-886D-B7DBC8552260Q37359459-FBFFCA3A-6B61-4D52-8173-827C891BEBE0Q37375005-556D94A7-73CB-4C38-80CD-E81FC6977B0CQ37776663-5EC0E719-C63C-4671-89B5-0836410B6430Q37797475-75DE327C-3D88-4488-BAB7-93A2FF76267FQ37866927-82F70F06-C03B-4D9E-9DAC-D4ED4ED83634Q37986238-BB84DC3E-47E9-4B9D-ACDA-E99675DFE4D8Q38010055-FCDE907B-A7BB-470A-9303-D9F51ED19A36Q38114478-F291BDD1-40B8-4ACB-92FD-FFD42C57BEFCQ38374758-AE498558-3800-470C-8585-0EE40C5062B2Q38389975-CF52CE90-8F65-4505-8A79-3255A98234E1Q38636369-73B2A2A3-45D8-4055-9FB7-8A89F6477CB1Q38909210-8FA7C597-8014-476A-A7BD-4C064D613A15Q39417367-C22D5B0C-9B5F-43B2-BF96-650728243DAEQ39449414-313FC132-1C2A-48E7-ADD4-85CB0A445C1F
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The thalidomide saga.
@ast
The thalidomide saga.
@en
type
label
The thalidomide saga.
@ast
The thalidomide saga.
@en
prefLabel
The thalidomide saga.
@ast
The thalidomide saga.
@en
P1476
The thalidomide saga.
@en
P2093
Magda Melchert
P304
P356
10.1016/J.BIOCEL.2007.01.022
P577
2007-01-30T00:00:00Z